A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Diabetic Neuropathic Pain.
Phase of Trial: Phase III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Bial
- 17 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 29 Nov 2013 Planned end date changed from Sep 2013 to Nov 2013 as reported by ClinicalTrials.gov.
- 22 Jul 2013 Planned end date changed from 1 Apr 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.